Do GLP-1s cause depression or suicidal thoughts?

Not at a population level, on the evidence so far. Reports from European regulators and US case reports prompted an FDA investigation opened in late 2023, and its January 2024 findings did not find evidence that GLP-1 receptor agonists cause suicidal thoughts or actions. No new warning was required. A study of 240,618 GLP-1 users in the TriNetX record network found lower rates of new suicidal ideation than non GLP-1 weight management. The population is heterogeneous, so individual experience can still differ from the average.

Why do I feel emotionally flat on a GLP-1?

Emotional flattening is one of the patterns people describe most often: fewer highs and fewer lows. Some experience it as a useful calm and others as the loss of what made them feel alive. Part of it overlaps with a separate change, the reduced interest in food as comfort. That is the drug doing its job, but food carries emotional roles too, and losing those roles can produce a sense of loss that looks like depression from the inside.

Can a GLP-1 make you irritable?

Some people report irritability in the 24 to 48 hours after an injection. The mechanism is unclear and it has not been isolated in trial data. Anxiety about the body changing, a new mirror and sometimes new attention from others is a separate and common adjustment that can read as the same thing.

What should I track if my mood feels different on a GLP-1?

Four things, once a week. Your mood baseline on a 1 to 10 scale, scored without comparing to last week. Whether the activities that usually bring you pleasure still do. Whether you are waking or going to bed more anxious. And your sleep, which deteriorates mood faster than almost any other input. If you feel meaningfully worse on the drug, flatter, more anxious or more irritable, take that record to your prescriber rather than waiting it out.

Mood, anxiety, and GLP-1s: what the data actually shows

The 30-second summary

Reports of mood changes, depression, and suicidal thoughts in GLP-1 users prompted an FDA safety review in 2024.

The review and several large independent analyses found no clear evidence that GLP-1s cause suicidality at a population level. The signal in early reports appears to have been driven by reporting bias.

Individual experience may differ from population averages. If you feel meaningfully worse on the drug, flatter, more anxious, more irritable, track it and tell your prescriber.

How the conversation started

In 2023, reports from European regulators and individual case reports in the United States described patients on GLP-1s who developed suicidal ideation or worsening depression. The FDA opened a formal investigation in late 2023 and published its findings in January 2024.

The FDA's review of available evidence, including U.S. post-marketing reports, manufacturer data, and external studies, did not find evidence that GLP-1 receptor agonists cause suicidal thoughts or actions. The agency continued to monitor the issue but did not require a new warning. (FDA, Update on FDA's ongoing evaluation of reports of suicidal thoughts, January 2024.)

Several large independent analyses arrived at similar conclusions:

A study using the U.S. TriNetX electronic health record network of 240,618 GLP-1 users with overweight or obesity found lower rates of new suicidal ideation in GLP-1 users compared with non-GLP-1 weight management. (Wang W et al., Nature Medicine 2024.)
An analysis of the WHO VigiBase pharmacovigilance database, while flagging a higher reporting rate, noted strong confounding by the underlying depression risk in the obese population.

The current best estimate: GLP-1s do not cause depression or suicidality at a population level. The population is heterogeneous, and individuals may have very different experiences.

What individual women report

The aggregate data is reassuring. The individual variance is real.

The patterns women describe most often in mood-related effects on a GLP-1:

Emotional flattening. Less highs, less lows. Some women describe it as a useful calm; others describe it as a loss of the things that made them feel alive.
Reduced interest in food-as-comfort. This is a feature of the drug, not a bug, appetite is supposed to be reduced. But food has emotional roles too, and losing those roles can produce a sense of loss that overlaps with depression.
Anxiety about weight changes. New body, new mirror, sometimes new attention from others. This can be its own emotional adjustment.
Irritability, especially in the 24 to 48 hours after an injection. Some women report this; the mechanism is unclear.

These experiences are real. They are not the same as the suicidality signal the FDA was investigating.

What to track

If you start a GLP-1 and want to be a good observer of yourself, four things are worth a weekly check-in:

Mood baseline. On a 1 to 10 scale, where would you put your average mood this week? Without comparison to last week.
Anhedonia signal. Are the activities that usually bring you pleasure still bringing it?
Anxiety. Are you waking up more anxious? Going to bed more anxious?
Sleep. Bad sleep deteriorates mood faster than almost any other input.

A monthly trend in these four numbers is the most useful thing you can bring to your prescriber if mood becomes a concern.

What to talk to your prescriber about

If you experience any of the following, this is not a footnote, it is the headline of your next appointment:

New or worsening depression
New thoughts of self-harm or suicide
Severe anxiety that interferes with daily life
A sudden change in mood after starting or escalating the medication

The response from your prescriber will usually be one of three things:

Pause the GLP-1 to see if the mood symptoms resolve. This is the cleanest diagnostic. Most prescribers will do this if the effect is significant.
Continue and monitor, especially if your underlying weight-loss trajectory is helping other aspects of your life and the mood effect is mild.
Add support: a therapist, a psychiatrist, sometimes antidepressant medication. The drug may not be the only problem to solve.

For women with a personal history of depression, eating disorders, or anxiety disorders, a baseline conversation about mental health with your prescriber before starting a GLP-1 is the right move. Not because the drug is contraindicated, it is not, but because you want a shared baseline against which to read the experience.

Eating disorders: a separate, serious consideration

GLP-1s reduce appetite. For a woman in recovery from an eating disorder, that reduction can be a trigger for relapse, even if the medication is being taken for the right medical reasons.

The Royal College of Psychiatrists and U.S. eating-disorder societies have published cautious statements: GLP-1s should not be prescribed to women with active anorexia nervosa, and women in recovery from any eating disorder should have their treatment team involved in the decision.

This is an area where the right answer depends entirely on the individual. There is no general rule. There is a careful, multidisciplinary conversation.

What to do with this

Mood is one of the symptoms the calculator asks about, and it is not decoration: a hard week changes the portioning and, in some cases, suspends the deficit. Being asked about it is the point, because the alternative is a target that assumes every week is the same.

Tell it about this week

Sources

FDA. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. January 2024. FDA
Wang W et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine 2024. Nature Medicine
EMA. Outcome of review on suicidal thoughts and GLP-1 agonists, April 2024. EMA

Medical disclaimer: Mental-health symptoms are not a footnote of a weight-loss journey. Take them to your prescriber or a mental-health professional promptly. See our full medical disclaimer.